Samsung Biologics Closes Polypeptide Tender Offer… "Public Offers Exceed 90%"

조선일보

Lean Right

Factuality

Ownership

Samsung Biologics has secured a 97.98% stake in Polypeptide Group, a global peptide contract development and manufacturing organization (CDMO), through a tender offer. With the requirements for compulsory purchase of the remaining shares now met, the acquisition process has entered its final stages. The plan is to close the transaction as early as the end of this year or no later than the first quarter of next year, subject to approval procedure…

연합뉴스-Yonhap News Agency

Lean Right

Factuality

Ownership

(Seoul = Yonhap News) Reporter Shin Seon-mi = Samsung Biologics [207940] in the tender offer for global peptide contract development and manufacturing organization (CDMO) Polypeptide Group...